Treatment with sitagliptin increased plasma levels of stromal-derived factor-1α (SDF-1α) and circulating endothelial progenitor cells, while also reducing plasma monocyte chemoattractant protein-1, a proinflammatory chemokine, in patients with type 2 diabetes mellitus[59]. The gene discussed is CCL2; the disease is type 2 diabetes mellitus.